Yaacov Michlin serves as Yissum's President and Chief Executive Officer since 2009. Michlin has been leading more than 300 licensing deals and the creation of more than 40 start up companies. Recnetly, Michlin led the creation and capital raising of Yissum's new holding company in the biotech area -Integra that acts as VC to fund biotech projects of HU and Agrinnovation that funds and invests in start up in the Agritech area. Michlin serves as chairman of Integra and Agrinnovation who manage $20 million investments. Michlin also led Yissum to the signing of long term collaborations with Roche, P&G , Coca Cola and other multinational companies. Michlin currently serves as chairman of Qlight Nanotech (in strategic collaboration with Merck) and Avraham Pharma (PIIb MCI Product) and as board member of few of Yissum leading spin-off companies in the biotech, agriculture and other fields. In May 2015 Michlin resigned from his role as co-chairman of the Israeli Tech Transfer Organization after 3 years in which he managed to increase substantially the activities and marketing of the ITTN. Before joining Yissum, Yaacov was involved in consulting to pharmaceutical, hi-tech and biomedical companies (including Teva, Bioline, CBI and Brainsway) in various technology commercialization deals, licensing agreements, capital raising, mergers and acquisitions and joint venture collaborations. Michlin holds a Bachelor of Law and Economics, cum laude, and a Master of Law degree, both from Bar-Ilan University, Israel, and a MBA, cum laude, from the Technion Israel Institute of technology.